S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Zogenix Stock Forecast, Price & News

-0.02 (-0.08%)
(As of 01/21/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
9.11 million shs
Average Volume
3.99 million shs
Market Capitalization
$1.45 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter.

Zogenix logo

About Zogenix

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$13.64 million
Book Value
$6.64 per share


Net Income
$-209.38 million
Net Margins
Pretax Margin




Free Float
Market Cap
$1.45 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.86 out of 5 stars

Medical Sector

775th out of 1,418 stocks

Pharmaceutical Preparations Industry

375th out of 683 stocks

Analyst Opinion: 3.2Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

Is Zogenix a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Zogenix stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZGNX, but not buy additional shares or sell existing shares.
View analyst ratings for Zogenix
or view top-rated stocks.

How has Zogenix's stock been impacted by COVID-19 (Coronavirus)?

Zogenix's stock was trading at $22.69 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ZGNX shares have increased by 14.5% and is now trading at $25.98.
View which stocks have been most impacted by COVID-19

When is Zogenix's next earnings date?

Zogenix is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Zogenix

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) released its quarterly earnings data on Thursday, November, 4th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.96) by $0.08. The business earned $22.61 million during the quarter, compared to analysts' expectations of $22.71 million. Zogenix had a negative net margin of 381.69% and a negative trailing twelve-month return on equity of 80.20%. The firm's quarterly revenue was up 690.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.02) EPS.
View Zogenix's earnings history

What price target have analysts set for ZGNX?

9 equities research analysts have issued 1-year price targets for Zogenix's stock. Their forecasts range from $17.67 to $62.00. On average, they expect Zogenix's share price to reach $32.10 in the next twelve months. This suggests a possible upside of 23.5% from the stock's current price.
View analysts' price targets for Zogenix
or view top-rated stocks among Wall Street analysts.

Who are Zogenix's key executives?

Zogenix's management team includes the following people:
  • Stephen James Farr, President, Chief Executive Officer & Director
  • Ashish M. Sagrolikar, Chief Operating Officer & Executive Vice President
  • Michael Patrick Smith, Chief Financial Officer, Treasurer & Executive VP
  • Bradley S. Galer, Chief Medical Officer & Executive Vice President
  • Steven A. Johnson, Vice President, Legal Council & Compliance Office

What is Stephen Farr, Ph.D.'s approval rating as Zogenix's CEO?

7 employees have rated Zogenix CEO Stephen Farr, Ph.D. on Glassdoor.com. Stephen Farr, Ph.D. has an approval rating of 85% among Zogenix's employees.

What other stocks do shareholders of Zogenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals (GWPH), Gilead Sciences (GILD), Vanda Pharmaceuticals (VNDA), AbbVie (ABBV), QUALCOMM (QCOM), Advanced Micro Devices (AMD), (CGC), Sorrento Therapeutics (SRNE), Southwest Airlines (LUV) and Micron Technology (MU).

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

Who are Zogenix's major shareholders?

Zogenix's stock is owned by many different institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (0.44%), HealthInvest Partners AB (0.35%) and DNB Asset Management AS (0.02%). Company insiders that own Zogenix stock include Ashish M Sagrolikar, Cam L Garner, Erle T Mast, Mark C Wiggins and Renee P Tannenbaum.
View institutional ownership trends for Zogenix

Which major investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including HealthInvest Partners AB, and DNB Asset Management AS. Company insiders that have sold Zogenix company stock in the last year include Erle T Mast, and Renee P Tannenbaum.
View insider buying and selling activity for Zogenix
or view top insider-selling stocks.

Which major investors are buying Zogenix stock?

ZGNX stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. Company insiders that have bought Zogenix stock in the last two years include Ashish M Sagrolikar, Cam L Garner, Mark C Wiggins, and Renee P Tannenbaum.
View insider buying and selling activity for Zogenix
or or view top insider-buying stocks.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $25.98.

How much money does Zogenix make?

Zogenix has a market capitalization of $1.45 billion and generates $13.64 million in revenue each year. The company earns $-209.38 million in net income (profit) each year or ($4.35) on an earnings per share basis.

How many employees does Zogenix have?

Zogenix employs 218 workers across the globe.

What is Zogenix's official website?

The official website for Zogenix is www.zogenix.com.

Where are Zogenix's headquarters?

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at (510) 550-8300, via email at [email protected], or via fax at 858-259-1166.

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.